Wegovy is also approved to lower the risk of heart attack and stroke in adults with cardiovascular disease who have either obesity or overweight
Email Human Email at [email protected] is monitored, and the reply I got was seemingly from a real person
But briefly, theres growing evidence that GLP-1 receptor agonists may reduce alcohol consumption, possibly help with other substance use, and potentially address some of the reward dysregulation that underlies both obesity and addiction
however, no statistically significant difference was observed between the groups
Moreover, companies concentrate on approaches to enlarging indications, enhancing marketing initiatives, and ensuring greater compliance through delivery systems
If you are not achieving the desired weight loss on the dose you are taking, and you havent yet reached either the 1.7 mg or 2.4 mg strength, continue following the Wegovy dosage schedule